FDA Approves Alcon’s Tryptyr for Dry Eye Disease

Today, the FDA approved Tryptyr (acoltremon ophthalmic solution 0.003%), a new eye drop developed by Alcon, for the treatment of both signs and symptoms of Dry Eye Disease (DED).

Formerly known as AR-15512, Tryptyr is the first FDA-approved treatment in a new class of eye drops that target TRPM8 receptors, stimulating corneal sensory nerves to boost the body’s natural tear production, according to a news release by Alcon.

The product will be packaged in easy-to-use, single-dose vials, with the recommended dosage being one drop per eye, twice daily.

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to follow.

According to media reports